UK at the Threshold of molecular screening for cancer

The UK is standing on the brink of the Bright New World of molecular screening for occult cancer!  This summer, the NHS starts screening for more than 50 cancers using the “Galleri blood test”, developed by an American company called ‘GRAIL’ !  

However, Bjorn has concerns, and after an unsuccessful search for any declared ‘study aims’, of the above NHS/GRAIL initiative asks - Does finding the early signature of cancer always mean that the cancer is treatable?  

Furthermore, as the test will generate just as many true positives as false positive results, HOW do you confirm that the positive result was a 'false positive'?  He is trying to look at this 'trial' through the lens of the Wilson and Jungner criteria.  

Finally, we are standing up for the effectiveness of CTC and wonder why an American study, published in GUT report such shockingly poor results of the technology. 

References
Liu MC. multi-cancer detection using methylation signatures. Ann Onc 2020;31(6);745-59reader.elsevier.com/reader/sd/pii/S0923753420360580?token=F3C7F7E4DB0EA9F4057F53898B77091477DBA3B9DC1A316BA21393EB8FF6466B5CDDC4F38A0F49C9673C7400EB558C2C

Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: WHO; 1968www.who.int/bulletin/volumes/86/4/07-050112BP.pdf